Japan· JP-6179001F3034
ボリコナゾール
A voriconazole product containing ボリコナゾール, registered in Japan by 共和薬品工業, on the national reimbursement list. The same ATC class is registered in 18 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Voriconazole is registered in 18 of 19 countries.
Countries holding a registration under ATC J02AC03 (voriconazole), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 10 of them publish a price we can compare per daily dose
Voriconazole · ATC J02AC03
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of voriconazole costs, country by country.
Normalised to the WHO defined daily dose (0.4 g), the median price runs from $0.14 in Czechia to $86.21 in Switzerland — a ×609 gap.
- 5 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Voriconazole · price per daily dose (0.4 g)
USD · FX 28 Sept 2026
- CH Switzerland$86.21
- FR France$38.90
- IT Italy$12.20
- US United States$3.77 (acquisition cost)
- CZ Czechia$0.14
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ボリコナゾール
- Manufacturer
- 共和薬品工業
- Country
- Japan (JP)
- ATC code
- J02AC03
- ATC class
- Voriconazole
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
513 interactions on record for voriconazole.
Graded by severity as the source publishes them — 161 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Voriconazole · interactions on record
513 records
- 161 severe
- 229 moderate
- 10 minor
- 48 info
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- NaloxegolA06AH03severe
65 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Voriconazole in 18 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaVFENDPfizer Europe MA EEIG, Bruxelles
- United StatesVFENDRoerig
- United KingdomVFEND 200mg powder and solvent for solution for infusion vialsPfizer Ltd
- SpainVFEND 200 mg COMPRIMIDOS RECUBIERTOS CON PELICULAPfizer Europe Ma Eeig
- NetherlandsVedida 200 mg poeder voor oplossing voor infusieMedochemie Limited
- BelgiumSpionic 200 mgPfizer
- FinlandVFENDParanova Oy
- GermanyVoriconazol 1 A Pharma1 A Pharma Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 31 EEA countries. Names it is sold under:
- Austria · Voriconazol Accord, Voriconazol Accordpharma
- Belgium · Voriconazol Eg, Voriconazol Fosun Pharma
- Bulgaria · Voriconazole Sandoz, Voriconazole Sanexcel
- Cyprus · Vedida, Voriconazole Accord
- Czechia · Voriconazol Viatris, Voriconazole Accord
- Germany · Voriconazol 1 A Pharma, Voriconazol Accord
- Denmark · Voriconazol "denk", Voriconazol Accordpharma
- Estonia · Vedida, Voriconazole Accord
- Spain · Voriconazol Accord, Voriconazol Aurovitas
- Finland · Voriconazol Accordpharma, Voriconazole Accord
- France · Voriconazole Accord, Voriconazole Amarox
- United Kingdom (Northern Ireland) · Voriconazole, Voriconazole Accord
- Greece · Aetopia, Voriconazole Aenorasis
- Croatia · Voramol, Vorikonazol Accordpharma
- Hungary · Voriconazole Accord, Voriconazole Onkogen
- Ireland · Voriconazole, Voriconazole Accord
- Iceland · Vfend, Voriconazol Accordpharma
- Italy · Voriconazolo Amarox, Voriconazolo Aurobindo
- Liechtenstein · Vfend, Voriconazole Accord
- Lithuania · Voriconazole Accord Healthcare, Voriconazole Teva
- Luxembourg · Voriconazol Eg, Voriconazol Renantos Stada Arzneimittel Ag
- Latvia · Voriconazole Accord Healthcare, Voriconazole Elpen
- Malta · Voriconazole Ahcl, Voriconazole Ibisqus
- Netherlands · Verria, Voramol
- Norway · Vfend, Voriconazol Accordpharma
- Poland · Voriconazol Polpharma, Voriconazole Accord
- Portugal · Voriconazol Accord, Voriconazol Aristo
- Romania · Vedida, Voramol
- Sweden · Voriconazole Accord, Voriconazole Fresenius Kabi
- Slovenia · Vorikonazol Accord, Vorikonazol Accordpharma
- Slovakia · Vedida, Voriconazol Hameln
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cf48f53b-8e28-4a94-aa9b-8b94ee088760 GET /v1/drugs/cf48f53b-8e28-4a94-aa9b-8b94ee088760?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "100mg1錠",
"marks": "局",
"source": "mhlw",
"remarks": null,
"yj_code": "6179001F3034",
"category": "内用薬",
"price_yen": 199.6,
"generic_name": "ボリコナゾール",
"product_name_jp": null,
"therapeutic_class": "6179",
"transitional_expiry": null
}See everything about voriconazole.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.